Innate networking: Thrombotic microangiopathy, the activation of coagulation and complement in the sensitized kidney transplant recipient

Meri, 2013, Complement activation in diseases presenting with thrombotic microangiopathy, Eur J Intern Med, 24, 496, 10.1016/j.ejim.2013.05.009 George, 2014, Syndromes of thrombotic microangiopathy, N Engl J Med, 371, 654, 10.1056/NEJMra1312353 Chiurchiu, 2002, Thrombotic microangiopathy in renal transplantation, Ann Transplant, 7, 28 Tanabe, 2002, Prospective analysis of thrombotic microangiopathy after renal transplantation: comparison between cyclosporine and tacrolimus immunosuppression, Transplant Proc, 34, 1819, 10.1016/S0041-1345(02)03089-0 Ashman, 2009, Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy, Am J Transplant, 9, 424, 10.1111/j.1600-6143.2008.02482.x Caires, 2012, De novo thrombotic microangiopathy after kidney transplantation: clinical features, treatment, and long-term patient and graft survival, Transplant Proc, 44, 2388, 10.1016/j.transproceed.2012.07.039 Hutton, 1970, Renal homotransplant rejection associated with microangiopathic haemolytic anaemia, Br Med J, 3, 87, 10.1136/bmj.3.5714.87 Pillay, 1973, Selective thrombocytopenia due to localised microangiopathy of renal allografts, Lancet, 302, 988, 10.1016/S0140-6736(73)91088-X Ikeda, 2016, Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab, Nephrology (Carlton), 10.1111/nep.12768 Wu, 2015, The inferior impact of antibody-mediated rejection on the clinical outcome of kidney allografts which develop de novo thrombotic microangiopathy, Clin Transplant Kerr, 2012, Complement-mediated injury and protection of endothelium: lessons from atypical haemolytic uraemic syndrome, Immunobiology, 217, 195, 10.1016/j.imbio.2011.07.028 Williams, 2016, Pathology consultation on the diagnosis and treatment of thrombotic microangiopathies (TMAs), Am J Clin Pathol, 145, 158, 10.1093/ajcp/aqv086 Ho, 2005, Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation, Biol Blood Marrow Transplant, 11, 571, 10.1016/j.bbmt.2005.06.001 Chua, 2015, Complement factor C4d is a common denominator in thrombotic microangiopathy, J Am Soc Nephrol, 26, 2239, 10.1681/ASN.2014050429 Satoskar, 2010, De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection, Am J Transplant, 10, 1804, 10.1111/j.1600-6143.2010.03178.x McCall, 2003, Prognostic significance of microvascular thrombosis in donor kidney allograft biopsies, Transplantation, 75, 1847, 10.1097/01.TP.0000063126.88887.68 Soares, 2016, Successful renal transplantation of deceased donor kidneys with 100% glomerular fibrin thrombi and acute renal failure due to disseminated intravascular coagulation, Transplantation Meehan, 2011, Thrombotic microangiopathy and peritubular capillary C4d expression in renal allograft biopsies, Clin J Am Soc Nephrol, 6, 395, 10.2215/CJN.05870710 Haas, 2014, Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions, Am J Transplant, 14, 272, 10.1111/ajt.12590 Haas, 2016, The revised (2013) Banff classification for antibody-mediated rejection of renal allografts: update, difficulties, and future considerations, Am J Transplant, 16, 1352, 10.1111/ajt.13661 Ezzelarab, 2006, Extended coagulation profiles of healthy baboons and of baboons rejecting GT-KO pig heart grafts, Xenotransplantation, 13, 522, 10.1111/j.1399-3089.2006.00342.x Lin, 2009, Coagulation dysregulation as a barrier to xenotransplantation in the primate, Transpl Immunol, 21, 75, 10.1016/j.trim.2008.10.008 Ezzelarab, 2011, Thrombocytopenia after pig-to-baboon liver xenotransplantation: where do platelets go?, Xenotransplantation, 18, 320, 10.1111/j.1399-3089.2011.00679.x Ekser, 2012, Potential factors influencing the development of thrombocytopenia and consumptive coagulopathy after genetically modified pig liver xenotransplantation, Transpl Int, 25, 882, 10.1111/j.1432-2277.2012.01506.x Cooper, 2016, The pathobiology of pig-to-primate xenotransplantation: a historical review, Xenotransplantation Orandi, 2016, Splenic irradiation for the treatment of severe antibody-mediated rejection, Am J Transplant, 10.1111/ajt.13882 Garg, 2017, Defining the phenotype of antibody-mediated rejection in kidney transplantation: advances in diagnosis of antibody injury, Transplant Rev, 31, 257, 10.1016/j.trre.2017.08.005 Zhu, 2005, The ancient origin of the complement system, EMBO J, 24, 382, 10.1038/sj.emboj.7600533 Rose, 2000, Venular thrombosis is the key event in the pathogenesis of antibody-mediated cardiac rejection, Xenotransplantation, 7, 31, 10.1034/j.1399-3089.2000.00042.x Walport, 2001, Complement. First of two parts, N Engl J Med, 344, 1058, 10.1056/NEJM200104053441406 Walport, 2001, Complement. Second of two parts, N Engl J Med, 344, 1140, 10.1056/NEJM200104123441506 Ricklin, 2016, Complement in disease: a defence system turning offensive, Nat Rev Nephrol, 12, 383, 10.1038/nrneph.2016.70 Chowdhury, 2003, Complement in renal transplantation, Nephron Clin Pract, 95, c3, 10.1159/000073012 Janeway, 2001 Kemper, 2003, Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype, Nature, 421, 388, 10.1038/nature01315 Marsh, 2001, The allogeneic T and B cell response is strongly dependent on complement components C3 and C4, Transplantation, 72, 1310, 10.1097/00007890-200110150-00022 Pratt, 2002, Local synthesis of complement component C3 regulates acute renal transplant rejection, Nat Med, 8, 582, 10.1038/nm0602-582 Galvan, 2012, C1q and phagocytosis: the perfect complement to a good meal, J Leukoc Biol, 92, 489, 10.1189/jlb.0212099 Nonaka, 2014, Evolution of the complement system, Subcell Biochem, 80, 31, 10.1007/978-94-017-8881-6_3 Posma, 2016, Coagulation and non-coagulation effects of thrombin, J Thromb Haemost, 10.1111/jth.13441 Navarro-Alvarez, 2016, The effects of exogenous administration of human coagulation factors following pig-to-baboon liver xenotransplantation, Am J Transplant, 16, 1715, 10.1111/ajt.13647 Lintner, 2016, Early components of the complement classical activation pathway in human systemic autoimmune diseases, Front Immunol, 7, 36, 10.3389/fimmu.2016.00036 Thomas, 2015, An anti-C1s monoclonal, TNT003, inhibits complement activation induced by antibodies against HLA, Am J Transplant, 15, 2037, 10.1111/ajt.13273 Yamakuchi, 2007, Antibody to human leukocyte antigen triggers endothelial exocytosis, Proc Natl Acad Sci U S A, 104, 1301, 10.1073/pnas.0602035104 Naemi, 2013, Anti-donor HLA class I antibodies: pathways to endothelial cell activation and cell-mediated allograft rejection, Transplantation, 96, 258, 10.1097/TP.0b013e3182985504 Kaplanski, 1998, Thrombin-activated human endothelial cells support monocyte adhesion in vitro following expression of intercellular adhesion molecule-1 (ICAM-1; CD54) and vascular cell adhesion molecule-1 (VCAM-1; CD106), Blood, 92, 1259, 10.1182/blood.V92.4.1259 Hamer, 2012, Human leukocyte antigen-specific antibodies and gamma-interferon stimulate human microvascular and glomerular endothelial cells to produce complement factor C4, Transplantation, 93, 867, 10.1097/TP.0b013e31824b3762 Naji, 2005, Induction of tissue factor expression on human umbilical vein endothelial cells by cell-specific HLA class I antibody: preliminary data, Transplant Proc, 37, 2892, 10.1016/j.transproceed.2005.08.001 Ruggeri, 2007, The role of von Willebrand factor in thrombus formation, Thromb Res, 120, S5, 10.1016/j.thromres.2007.03.011 Nightingale, 2013, The secretion of von Willebrand factor from endothelial cells; an increasingly complicated story, J Thromb Haemost, 11, 192, 10.1111/jth.12225 van Schie, 2011, Genetic determinants of von Willebrand factor levels and activity in relation to the risk of cardiovascular disease: a review, J Thromb Haemost, 9, 899, 10.1111/j.1538-7836.2011.04243.x Sonneveld, 2014, Von Willebrand factor and ADAMTS13 in arterial thrombosis: a systematic review and meta-analysis, Blood Rev, 28, 167, 10.1016/j.blre.2014.04.003 Bendapudi, 2015, Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative, Br J Haematol, 171, 836, 10.1111/bjh.13658 Huber-Lang, 2017, Auxiliary activation of the complement system and its importance for the pathophysiology of clinical conditions, Semin Immunopathol Huber-Lang, 2006, Generation of C5a in the absence of C3: a new complement activation pathway, Nat Med, 12, 682, 10.1038/nm1419 Foley, 2016, Complement activation in arterial and venous thrombosis is mediated by plasmin, EBioMedicine, 5, 175, 10.1016/j.ebiom.2016.02.011 Krisinger, 2012, Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway, Blood, 120, 1717, 10.1182/blood-2012-02-412080 Peerschke, 2008, Platelet mediated complement activation, Adv Exp Med Biol, 632, 81 Hattori, 1989, Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface, J Biol Chem, 264, 9053, 10.1016/S0021-9258(18)81901-9 Noone, 2016, Von Willebrand factor regulates complement on endothelial cells, Kidney Int, 90, 123, 10.1016/j.kint.2016.03.023 Sis, 2009, Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining, Am J Transplant, 9, 2312, 10.1111/j.1600-6143.2009.02761.x Lidington, 2000, Induction of decay-accelerating factor by thrombin through a protease-activated receptor 1 and protein kinase C-dependent pathway protects vascular endothelial cells from complement-mediated injury, Blood, 96, 2784, 10.1182/blood.V96.8.2784 Lidington, 2005, A role for proteinase-activated receptor 2 and PKC-epsilon in thrombin-mediated induction of decay-accelerating factor on human endothelial cells, Am J Physiol Cell Physiol, 289, C1437, 10.1152/ajpcell.00502.2004 Carson, 1990, Consecutive enzyme cascades: complement activation at the cell surface triggers increased tissue factor activity, Blood, 76, 361, 10.1182/blood.V76.2.361.361 Ikeda, 1997, C5a induces tissue factor activity on endothelial cells, Thromb Haemost, 77, 394, 10.1055/s-0038-1655974 Hamilton, 1990, Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex, J Biol Chem, 265, 3809, 10.1016/S0021-9258(19)39666-8 Sims, 1988, Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity, J Biol Chem, 263, 18205, 10.1016/S0021-9258(19)81346-7 Rataj, 2016, Inhibition of complement component C5 prevents clotting in an ex vivo model of xenogeneic activation of coagulation, Xenotransplantation, 23, 117, 10.1111/xen.12218 Krarup, 2007, Simultaneous activation of complement and coagulation by MBL-associated serine protease 2, PLoS One, 2, 10.1371/journal.pone.0000623 Hess, 2012, Effects of MASP-1 of the complement system on activation of coagulation factors and plasma clot formation, PLoS One, 7, 10.1371/journal.pone.0035690 Gulla, 2010, Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot, Immunology, 129, 482, 10.1111/j.1365-2567.2009.03200.x Kozarcanin, 2016, The lectin complement pathway serine proteases (MASPs) represent a possible crossroad between the coagulation and complement systems in thromboinflammation, J Thromb Haemost, 14, 531, 10.1111/jth.13208 Cugno, 2001, In vitro interaction of C1-inhibitor with thrombin, Blood Coagul Fibrinolysis, 12, 253, 10.1097/00001721-200106000-00005 Caccia, 2011, Interaction of C1 inhibitor with thrombin on the endothelial surface, Blood Coagul Fibrinolysis, 22, 571, 10.1097/MBC.0b013e3283494ba7 Davis, 2004, Biological effects of C1 inhibitor, Drug News Perspect, 17, 439, 10.1358/dnp.2004.17.7.863703 van der Graaf, 1983, Inactivation of kallikrein in human plasma, J Clin Invest, 71, 149, 10.1172/JCI110743 Paran, 2005, Venous and arterial thrombosis following administration of intravenous immunoglobulins, Blood Coagul Fibrinolysis, 16, 313, 10.1097/01.mbc.0000172694.85233.a8 Pusey, 2012, Plasmapheresis in immunologic renal disease, Blood Purif, 33, 190, 10.1159/000334155 Montgomery, 2016, Plasma-derived C1 esterase inhibitor for acute antibody-mediated rejection following kidney transplantation: results of a randomized double-blind placebo-controlled pilot study, Am J Transplant, 10.1111/ajt.13871 Wang, 2007, Inhibition of terminal complement components in presensitized transplant recipients prevents antibody-mediated rejection leading to long-term graft survival and accommodation, J Immunol, 179, 4451, 10.4049/jimmunol.179.7.4451 Stegall, 2011, Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients, Am J Transplant, 11, 2405, 10.1111/j.1600-6143.2011.03757.x Cornell, 2015, Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year, Am J Transplant, 15, 1293, 10.1111/ajt.13168 Tillou, 2010, Recombinant human C1-inhibitor prevents acute antibody-mediated rejection in alloimmunized baboons, Kidney Int, 78, 152, 10.1038/ki.2010.75 Vangerow, 2001, C1-Inhibitor for treatment of acute vascular xenograft rejection in cynomolgus recipients of h-DAF transgenic porcine kidneys, Xenotransplantation, 8, 266, 10.1034/j.1399-3089.2001.00130.x Fiane, 1999, C1-inhibitor attenuates hyperacute rejection and inhibits complement, leukocyte and platelet activation in an ex vivo pig-to-human perfusion model, Immunopharmacology, 42, 231, 10.1016/S0162-3109(99)00008-9 Caliezi, 2002, C1-inhibitor in patients with severe sepsis and septic shock: beneficial effect on renal dysfunction, Crit Care Med, 30, 1722, 10.1097/00003246-200208000-00008 Vo, 2015, A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients, Transplantation, 99, 299, 10.1097/TP.0000000000000592 Ito, 2016, Possible efficacy of recombinant human soluble thrombomodulin for the treatment of thrombotic microangiopathy after liver transplantation, Liver Transpl, 22, 689, 10.1002/lt.24411 Ito, 2016, Thrombomodulin as an intravascular safeguard against inflammatory and thrombotic diseases, Expert Opin Ther Targets, 20, 151, 10.1517/14728222.2016.1086750 Karegli, 2016, Thrombalexins: cell-localized inhibition of thrombin and its effects in a model of high-risk renal transplantation, Am J Transplant Burghuber, 2016, Antibody-mediated rejection in sensitized nonhuman primates: modeling human biology, Am J Transplant, 16, 1726, 10.1111/ajt.13688 Manook, 2017, Thrombalexin: use of a cytotopic anticoagulant to reduce thrombotic microangiopathy in a highly sensitized model of kidney transplantation, Am J Transplant, 10.1111/ajt.14234 Kassimatis, 2017, A double-blind randomised controlled investigation into the efficacy of Mirococept (APT070) for preventing ischaemia reperfusion injury in the kidney allograft (EMPIRIKAL): study protocol for a randomised controlled trial, Trials, 18, 255, 10.1186/s13063-017-1972-x Ekdahl, 2015, Thromboinflammation in therapeutic medicine, Adv Exp Med Biol, 865, 3, 10.1007/978-3-319-18603-0_1